博尼控股(01906.HK):預計2019年度將錄得虧損淨額
格隆匯2月28日丨博尼控股(01906.HK)發佈公告,集團預期截至2019年12月31日止年度將錄得公司擁有人應占虧損淨額,較2018年同期減少約150%的淨損益。
公告表示,2019年度預期錄得虧損主要是由於客户銷售訂單減少,導致集團海外及中國原始設計製造商銷售下跌;ODM銷售毛利率較2018年同期有所下跌;在湖南省設立工廠並於美國及中國香港設立銷售代表辦事處導致行政及銷售開支增加;及產生非經常性上市開支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.